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IMPORTANCE The optimal timing to operate in patients with asymptomatic severe aortic
stenosis (AS) remains controversial. Left ventricular global longitudinal strain (LV GLS) may
help to identify patients whomight benefit from undergoing earlier aortic valve replacement.
OBJECTIVE To investigate the prevalence of impaired LV GLS, the natural course of LV GLS,
and its prognostic implications in patients with asymptomatic severe AS with preserved left
ventricular ejection fraction (LVEF).
DESIGN, SETTING, AND PARTICIPANTS This registry-based study included the institutional
registries of 3 large tertiary referral centers and 220 patients with asymptomatic severe AS
and preserved LVEF (>50%) whowerematched for age and sex with 220 controls without
structural heart disease. The echocardiograms of patients and controls were performed
between 1998 and 2017.
EXPOSURES Both clinical and echocardiographic data were assessed retrospectively. Severe
AS was defined by an indexed aortic valve area less than 0.6 cm2/m2. Left ventricular global
longitudinal strain was evaluated on transthoracic echocardiography using speckle tracking
imaging.
MAIN OUTCOMES ANDMEASURES The prevalence of impaired LV GLS, the natural course of
LV GLS, and the association of impaired LV GLS with symptom onset and the need for aortic
valve intervention.
RESULTS Two hundred twenty patients (mean [SD] age, 68 [13] years; 126men [57%]) were
included. Despite comparable LVEF, LV GLS was significantly impaired in patients with
asymptomatic severe AS compared with age- and sex-matched controls without AS (mean
[SD] LV GLS, −17.9% [2.5%] vs −19.6% [2.1%]; P < .001). After a median follow-up of 12
(interquartile range, 7-23) months, mean (SD) LV GLS significantly deteriorated (−18.0%
[2.6%] to −16.3% [2.8%]; P < .001) while LVEF remained unchanged. Patients with impaired
LV GLS at baseline (>−18.2%) showed a higher risk for developing symptoms (P = .02) and
needing aortic valve intervention (P = .03) at follow-up compared with patients with more
preserved LV GLS (−18.2%).
CONCLUSIONS AND RELEVANCE Subclinical myocardial dysfunction that is characterized by
impaired LV GLS is often present in patients with asymptomatic severe AS with preserved
LVEF. Left ventricular global longitudinal strain further deteriorates over time and impaired
LV GLS at baseline is associated with an increased risk for progression to the symptomatic
stage and the need for aortic valve intervention.
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I n patients with asymptomatic severe aortic stenosis (AS),thecurrentguidelines recommendawatchfulwaitingstrat-egy until symptoms or left ventricular (LV) systolic dys-
function (ie, LVejection fraction [LVEF]<50%)develop.1,2 The
optimal timing for intervention in these patients remains
controversial.3-6 To determine whether the patients are truly
asymptomatic, exercise testing isan importantdiagnostic tool.7
However, in patients who are unable to perform this test, ad-
ditional measurements are needed to better define the tim-
ing of the intervention. The assessment of LV systolic func-
tion by means of global longitudinal strain (GLS) by speckle
tracking echocardiography has demonstrated that a signifi-
cant proportion of patients with severe AS have impaired LV
GLSdespitehavingnormalLVEF.8-13 ImpairedLVGLShasbeen
associated with worse outcomes in patients with sympto-
matic severe AS.14 However, to our knowledge, the preva-
lence of impaired LVGLS among patients with asymptomatic
severe AS and normal LVEF and the natural course and prog-
nosticvalueofLVGLS in this subgroupofpatientshasnotbeen
extensively elucidated. Accordingly, this study aimed to in-
vestigate the prevalence of impaired LV GLS, as well as de-
scribing the natural course of serial changes in LV GLS and its
prognostic implications, in asymptomatic patients with se-
vere AS and preserved LVEF.
Methods
Study Population and Data Collection
From amulticenter international registry of patients with AS
(LeidenUniversityMedical Center,Heart ValveClinic, and In-
stitut Universitaire deCardiologie et de Pneumologie deQué-
bec), 220 patients with asymptomatic severe AS and pre-
served LV ejection fraction (LVEF > 50%) were selected and
included in this retrospective study. Patients were selected
based on available echocardiographic data at baseline (de-
fined as the date of the first diagnosis of severeAS)with a fea-
sible speckle trackinganalysis. Thedefinitionof severeASwas
based on an indexed aortic valve area (AVA) of less than 0.6
cm2/m2 and/or a mean aortic valve gradient of 40 mm Hg or
more and/or a peak aortic jet velocity of 4 m per second or
more.2,15,16Whenavailable, the last transthoracic echocardio-
gramperformed at the outpatient clinic or before aortic inter-
ventionwas analyzed to evaluate the changes in valve hemo-
dynamics, LV structure, and systolic function (including LV
GLS).Measurements of the echocardiographic datawere per-
formed at each institution by experienced observers. Aortic
valve intervention was defined as a surgical or transcatheter
aortic valve replacement (AVR) or balloon valvuloplasty. The
exclusion criteria were AS-related symptoms at baseline (eg,
angina, syncope, ordyspnea), nonsevereAS, LVEFof less than
50%, having undergone prior aortic or mitral valve interven-
tion, acute endocarditis at baseline, or the inability to mea-
sure LV GLS.
In addition, an age- and sex-matched control groupof 220
individualswithout structural heart diseasewas includedand
used as a reference for measuring LV GLS. The transthoracic
echocardiograms of this group of individuals were per-
formed at the Leiden University Medical Center. The referral
reasons toperformechocardiography in this groupwereatypi-
cal chest pain, palpitations, or syncope without the presence
of a murmur.
Baselinepatientdemographics andclinical follow-updata
were gathered and analyzed retrospectively using thedepart-
mental patient information systemsandhospital records. This
retrospective analysis of clinically acquired data was ap-
proved by the respective institutional review boards of each
participating center, and consent was waived due to the ret-
rospective nature of the study.
Transthoracic Echocardiography
Transthoracic echocardiography was performed in all
patients at rest in the left decubitus position using commer-
cially available ultrasonography systems. Conventional LV
dimensions and function as well as AVA were measured fol-
lowing current recommendations.17 Additionally, LV GLS
was measured with a 2-dimensional speckle tracking analy-
sis on apical 2-, 3-, and 4- chamber views using commer-
cially available software (Leiden University Medical Center:
EchoPac, version 113; General Electric; Vingmed Ultrasound;
Heart Valve Clinic Liège and Institut Universitaire de Cardi-
ologie et de Pneumologie de Québec: 2D Cardiac Perfor-
mance Analysis; TomTec Imaging Systems).17 The frame rate
of the 2-dimensional echocardiographic data was 40 frames
per second or higher. Left ventricular GLS measures the
shortening of the myocardial fibers in the longitudinal direc-
tion and is conventionally presented as a negative value.
Therefore, a less negative LV GLS (ie, closer to 0) represents
worse LV systolic function.
Clinical and Echocardiographic Follow-up and End Points
Patientswere routinely followedupat theoutpatient clinic ac-
cording to guideline recommendations.16 The onset of AS-
related symptoms was recorded. The medical treatment and
timing for AVR was left at the discretion of the treating phy-
sician of each institution. The time to symptomdevelopment
and AVR, as well as the date of all-cause mortality, were re-
corded as clinical end points for assessing the prognosis.
Key Points
Question What is the natural course of left ventricular global
longitudinal strain (LV GLS) and prevalence and prognostic value
of impaired LV GLS in patients with asymptomatic severe aortic
stenosis (AS) and preserved left ventricular ejection fraction?
Findings In this registry-based study of 220 patients,
asymptomatic patients with severe AS showed significantly
impaired LV GLS compared with 220 controls with further
deterioration over time. Patients with impaired LV GLS at baseline
showed a higher risk for developing symptoms and requiring aortic
intervention.
Meaning Subclinical myocardial dysfunction that is characterized
by impaired LV GLS is often present in patients with asymptomatic
severe AS and is associated with symptom development and the
need for intervention.
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Statistical Analysis
Categorical variables were presented as numbers (percent-
age) and continuous variables as means (SD) if normally dis-
tributed or medians (interquartile range [IQR]) if otherwise.
Histogramswereusedtoevaluate if aGaussiandistributionwas
present. Comparisons between the total asymptomatic se-
vere AS group and the control group were performed using
the t test orMann-WhitneyU test for continuousvariables and
the χ2 test or Fisher exact test for categorical variables as ap-
propriate. Thegroupofpatientswith asymptomatic severeAS
wasdivided according to the symptomstatus at the last echo-
cardiogram performed: symptomatic vs asymptomatic.
Changes within and between these 2 groups were assessed
using linear mixed models, with correction for age, sex, and
time to follow-up. To further examine the prognostic value of
LVGLS, the studypopulationwasdividedaccording to theme-
dian baseline LV GLS value. Cumulative event rates were cal-
culatedwith the Kaplan-Meiermethod. Two end points were
defined: new onset of symptoms and AVR. Comparisons be-
tween the 2 groups were performed using log-rank tests. To
assess the association between baseline LV GLS and the end
points, Cox proportional hazards modeling was used. Spline
Table 1. Baseline Clinical and Echocardiographic Characteristics of PatientsWith Asymptomatic Severe Aortic










Age, y 67.9 (13.0) 65.7 (13.3) .08
Male, No. (%) 126 (57) 126 (57) >.99
Body surface area, m2 1.87 (0.2) 1.93 (0.2) .002
Hypertension, No. (%) 128 (59) 103 (48) .02
Hypercholesterolemia, No. (%) 103 (47) 54 (25) <.001
Diabetes, No. (%) 34 (16) 24 (11) .16
History of smoking, No. (%) 73 (38) 17 (11) <.001
Coronary artery disease, No. (%) 47 (22) 0 <.001
Prior myocardial infarction, No. (%) 15 (7) 0 <.001
Medication use, No. (%)
β-Blocker 78 (36) 49 (23) .002
ACE inhibitor/ARB II 88 (40) 65 (30) .02
Calcium antagonist 48 (22) 23 (11) .001
Diuretics 52 (24) 44 (20) .34
Statins 112 (51) 56 (26) <.001
Aspirin and/or clopidogrel 93 (43) 48 (22) <.001
Vitamin K antagonist or NOAC 31 (14) 3 (1) <.001
Creatinine level, IQR, mg/dL 0.91 (0.79-1.09) 0.90 (0.78-1.05) .56
Estimated GFR, IQR, mL/min/1.73 m2 76 (61-89) 80 (65-89) .48
Baseline Echocardiography
Valve anatomy, No. (%)
<.001Tricuspid 170 (77) 220 (100)
Bicuspid 50 (23) 0
Aortic valvea
Mean gradient, mm Hg 39.4 (12.6) NA NA
Peak velocity, m/s 4.0 (0.6) NA NA
Area, cm2 0.86 (0.1) NA NA
Area index, cm2/m2 0.46 (0.1) NA NA
Stroke volume, mLa 81.4 (17.1) NA NA
Stroke volume index, mL/m2a 43.8 (9.1) NA NA
Left ventricular end-diastolic
diameter, mm
45.4 (5.8) 48.5 (6.4) <.001
Left ventricular end-systolic
diameter, mm
28.2 (5.0) 30.5 (6.5) <.001
Intraventricular septal thickness, mm 12.9 (2.3) 10.3 (1.7) <.001
Posterior wall thickness, mm 11.6 (1.9) 10.0 (2.0) <.001
Left ventricular mass index, g/m2 112.0 (27.7) 92.5 (21.4) <.001
Left ventricular ejection fraction, % 61.5 (5.9) 62.1 (6.3) .27
Left ventricular global longitudinal
strain, %
−17.9 (2.5) −19.6 (2.1) <.001
Abbreviations: ACE,
angiotensin-converting enzyme;
ARB II, angiotensin II receptor
blocker; AS, aortic stenosis;
GFR, glomerular filtration rate
estimated using the Chronic Kidney
Disease Epidemiology Collaboration
formula; IQR, interquartile range;
NA, not applicable; NOAC, novel oral
anticoagulants.
SI conversion factor: To convert
creatinine to micromoles per liter,
multiply by 88.4.
a Aortic valve gradients, aortic valve
area, and stroke volumewere only
measured for patients with AS.
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models were fitted with overlaying confidence intervals for
each end point vs LV GLS on the log-hazards scale, adjusting
for age, sex, coronary artery disease, atrial fibrillation, and
LVmass index. SPSS, version 23.0 (IBM)was used for the sta-
tistical analyses. A P value of <.05 was considered statisti-
cally significant.
Results
Characteristics of PatientsWith Asymptomatic Severe AS
vs Controls
In total, 220 patients with asymptomatic severe AS and
preserved LVEF (mean [SD] age, 68 [13] years; 126 men
[57%]) were evaluated in this study (Table 1). Despite com-
parable LVEF, LV GLS was significantly impaired in the
patients with asymptomatic severe AS compared with con-
trols, suggesting that asymptomatic patients with severe AS
can harbor subtle myocardial dysfunction. When using the
mean LV GLS value of the control group as a reference to
define normal (≤−19.6%) or impaired LV longitudinal systolic
function (>−19.6%), 153 patients (70%) with asymptomatic
severe AS had impaired LV GLS. The mean (SD) value of LV
GLS was not significantly different across the centers (Lei-
den, −18.2% [2.3%]; Québec, −18.0% [1.8%]; Liège, −17.4%
[3.1%]; analysis of variance P = .15). In addition, there were
no differences across the centers in the proportion of
patients with impaired LV GLS (Leiden, 65%; Québec, 81%;
Liège, 73%; P = .20).
Changes in LV GLSOver Time in PatientsWith AS
Toevaluate the changes inLVGLS inpatientswith asymptom-
atic severe AS, a subgroup of 150 patients (68.2%) with se-
vere AS with an available second transthoracic echocardio-
gram result (at the last clinical follow-up or before AVR) and a
feasible speckle trackinganalysis resultwasevaluated.Theme-
dian time interval between the 2 echocardiograms was 12
months (IQR, 7-23). The changes in valve hemodynamics and
LV systolic function are displayed in eTable 1 in the Supple-
ment.Over time, thereweresignificant increases inmeantrans-
valvular gradients and LV mass index, whereas the AVA de-
creased. While the mean (SD) LVEF remained unchanged
(61.2% [5.7%] to 60.6% [7.6%]; P = .15), mean (SD) LV GLS
showed significant impairment over time (−18.0% [2.6%] to
−16.3% [2.8%]; P < .001) (Figures 1 and 2), demonstrating in-
creasing subclinical LV dysfunction over time.
Of the 150patientswith echocardiographic follow-upand
feasible speckle tracking analysis, 78 (52%) were sympto-
matic at follow-upechocardiographyand72patients (48%) re-
mained asymptomatic. Themedian (IQR) time from baseline
to follow-up echocardiography was similar between these
2 groups (symptomatic, 13 [8-28] months vs asymptomatic,
12 [6-20]months;P = .09). Comparedwith asymptomatic pa-
tients,patientswhodevelopedsymptomsat follow-upshowed
a higher prevalence of atrial fibrillation (22% vs 10%, respec-
tively; P = .05) and had more frequent coronary artery dis-
ease (27% vs 16%, respectively; P = .09). Table 2 outlines the
changes invalvehemodynamics andLVsystolic functionover
time in these patients divided by symptom status at follow-

















































































































Example of a patient with
asymptomatic severe aortic stenosis
and preserved left ventricular (LV)
ejection fraction (LVEF) at baseline
(A) and at follow-up (B). Over time,
the aortic stenosis severity and LV
hypertrophy progressed and LV
systolic function as assessed with
LV global longitudinal strain (GLS)
deteriorated, whereas LVEF
remained unchanged. LVMI indicates
left ventricular mass index.
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up. Within both groups, the progression of AS was observed
over time with a concomitant increase in LV mass index and
impairment inLVGLSwithout changes inLVEF.Betweenboth
groups, no significant differences were observed in valve he-
modynamics and LV systolic function, although LV mass in-
dex at follow-up was higher in patients with AS who devel-
oped symptoms.
Prognostic Value of LV GLS in SymptomDevelopment
and AVR
Of the 220 patients with asymptomatic severe AS, 118 (54%)
developed symptoms during a median follow-up of 12
months (IQR, 5-24). After a median follow-up period of 13
months (IQR, 6-25), 162 patients (74%) received an aortic
valve intervention (28 [17%] received transcatheter aortic
valve implantation, 130 [80%] underwent surgical AVR, and
4 [3%] underwent balloon valvuloplasty). Most of these
patients underwent aortic valve intervention because of
symptom development (104 [64%]) or progression of AS
severity (40 [25%]); only 18 patients (11%) received an AVR
because of other reasons, such as an indication for coronary
artery bypass grafting. During follow-up, 28 patients (13%)
died; 8 patients (4%) died while scheduled for AVR or when
receiving conservative treatment.
To evaluate the prognostic value of baseline LV GLS, the
study population was divided into 2 groups according to the
medianvalueof baselineLVGLS (morepreserved, ≤−18.2%vs
more impaired, >−18.2%) (eTable 2 in the Supplement). Com-
paredwithpatientswithmorepreservedLVGLS,patientswith
more impairedLVGLShadahigher prevalenceof coronary ar-
tery disease (30% vs 15%, P = .01) and atrial fibrillation (26%
vs 12%, P = .01). On transthoracic echocardiography, patients
with more impaired LV GLS had a larger LV mass index and
lower LVEF than patients with more preserved LV GLS, al-
thoughmeanLVEFwasmore than60%inbothgroups (eTable
2 in the Supplement).
Thecumulativeevent rates fordevelopingsymptomswere
significantly higher in patients with a baseline LV GLS more
than −18.2% compared with patients with an LV GLS −18.2%
or less (59%vs45%at 2-year follow-up, respectively, and91%
vs 79% at 5-year follow-up, respectively; log-rank P = .02)
(Figure3A). Similarly, forAVR, thecumulativeevent rateswere
significantly higher in patientswith impairedbaseline LVGLS
(>−18.2%) comparedwithpatientswithmorepreservedbase-
line LV GLS (≤−18.2%) after 2 years (66% vs 57%, respec-
Figure 2. Time Course of Valve Hemodynamics and Left Ventricular









































































Time course of valve hemodynamics in a subgroup of 150 patients with
asymptomatic severe aortic stenosis at baseline vs follow-up echocardiography
by aortic valve (AV) mean gradient (A), left ventricular (LV) hypertrophy (B) and
LV systolic function by LV ejection fraction (C), and LV global longitudinal strain
(GLS) (D).
a P < .001.
Table 2. Echocardiographic Parameters in 150 PatientsWith Asymptomatic Severe Aortic Stenosis at Baseline









P Value Baseline Follow-upBaseline Follow-up Baseline Follow-up
Aortic valve
Mean gradient, mm Hg 38.4 (11.6) 49.0 (15.8) <.001 39.4 (13.5) 46.6 (15.8) <.001 .71 .31
Peak velocity, m/s 3.9 (0.6) 4.4 (0.6) <.001 4.0 (0.6) 4.3 (0.6) <.001 .36 .25
Area, cm2 0.88 (0.1) 0.76 (0.1) <.001 0.85 (0.1) 0.79 (0.1) .05 .12 .30
Area index, cm2/m2 0.48 (0.1) 0.41 (0.1) <.001 0.46 (0.1) 0.42 (0.1) .02 .08 .41
Stroke volume, mL 81.1 (14.6) 80.6 (14.8) .17 81.7 (19.5) 82.1 (19.2) .71 .97 .91
Stroke volume index, mL/m2 44.6 (9.0) 43.7 (8.5) .34 43.6 (10.1) 43.5 (8.3) .94 .55 .84
LV
Mass index, g/m2 114.0 (27.1) 129.6 (29.2) <.001 113.7 (30.6) 121.0 (29.6) .01 .76 .06
Ejection fraction, % 61.4 (6.3) 61.6 (6.9) .25 61.0 (5.0) 59.5 (8.2) .28 .65 .06
Global longitudinal strain, % −17.7 (2.6) −16.3 (2.9) <.001 −18.2 (2.6) −16.4 (2.6) <.001 .21 .83
Abbreviations: AVR, aortic valve replacement; LV, left ventricular.
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tively) and5yearsof follow-up (96%vs82%, respectively; log-
rank P = .03) (Figure 3B). The spline curves to assess the
association between symptom development and aortic valve
intervention across a range of LV GLS are shown in the eFig-
ure in the Supplement. For both symptom development and
aortic valve intervention, the linearity assumption was not
violated (χ2, 0.83; P = .67, and χ2, 1.86; P = .41, respectively).
For symptomdevelopment, a plateau can be seen (eFigure in
the Supplement). For aortic valve intervention, a clear in-
crease in hazard ratios can be observed formore impaired LV
GLS (eFigure in the Supplement).
Discussion
This study demonstrated that in patients with asymptomatic
severe AS and preserved LVEF, LV GLS assessed by speckle
tracking imaging is impaired as compared with age- and sex-
matched controlswithout structural heart disease.Over time,
patients with asymptomatic severe AS showed a progression
ofAS severity accompaniedby increasingLVhypertrophyand
further impairment of LV GLS, while LVEF remained rela-
tively unchanged. Patients with impaired LV GLS at baseline
showed a higher risk for developing symptoms and for need-
ingaorticvalve interventionat follow-upascomparedwithpa-
tientswithmorepreservedLVGLS.These findings suggest that
LV GLS is a more sensitive marker for early myocardial dam-
age than LVEF in this patient group andmayhelp identify the
patients whomay benefit from earlier AVR.
LV GLS as aMarker for Subtle LV Dysfunction
in Asymptomatic Severe AS
Symptom development and LV systolic dysfunction are the
main factors thatdetermine the timingofAVR inpatientswith
severe AS.1,2 However, decreased physical activity in the ag-
ing AS population may result in the underrecognition or late
reporting of symptoms.18 Zilberszac et al19 demonstrated that
43%of elderly patientswith asymptomatic severeASwhode-
veloped symptomspresentedwith severe heart failure symp-
toms (New York Heart Association class ≥III). The deteriora-
tionofLVsystolic functiondefinedbyanLVEFof less than50%
can be regarded as a more objective parameter that indicates
theneed forAVR.However, thiswill only occurwhen the con-
centric remodeled left ventricle fails tomaintain normal wall
stressbecauseofsignificantafterloadmismatch.20At thisstage,
LV remodeling is characterized by progressive myocardial fi-
brosis,which isnot reversible after an intervention.21,22There-
fore, more sensitive markers of LV systolic dysfunction are
needed at an earlier stage to identify patients with severe AS
who are at risk for irreversible myocardial damage. Recently,
Stokke et al12 showed that by inducing concentric LV remod-
elingwith an increase inwall thickness and a reduction in di-
ameter of the LV cavity, the LVEF can remain preserved,
whereas LV GLS will be impaired. While the presence of im-
paired LV GLS with preserved LVEF has been described in
symptomatic severeAS,8,9,23 theprevalenceof impairedLVGLS
inasymptomatic severeAShasbeen less studied.Lafitte et al24
reported significantly impaired LV GLS in 65 patients with
asymptomatic severe AS compared with 60 healthy partici-
pants (−17.8% [3.5%] vs −21.1% [1.8%], respectively; P < .05),
while no differences were observed in LVEF (64% [7%] vs
66% [5%], respectively).24 This study extends these findings
in a larger population. However, the mean value of LV GLS in
this studywasmore preserved than that reported in previous
studies (−18.0%vs−15%to−16.6%).25-29Thisdiscrepancycould
be explained by the inclusion of older patients in those
studies. Furthermore, to our knowledge, this study is the
first to report sequential measurements of LV GLS in the pe-
riod between the initial AS diagnosis and intervention and to
demonstrate a clear deterioration of LVGLSwithout a decline
in LVEF.
Prognostic Value of LV GLS in Patients
With Asymptomatic Severe AS
Multiple echocardiographic predictors ofmortality and other
adverse cardiac events have been identified in asymptomatic
severeASwithpreservedLVEF (ie, peakaortic jet velocity>5.0
m/s,4,19,30,31 aortic valve calcification,27,32 small AVA,33 inap-
Figure 3. Kaplan-Meier Estimates for Event Rates for Symptom












































































Log-rank test; P = .03
Log-rank test; P = .02
Kaplan-Meier estimates for event rates for symptom development (A) and
intervention (B) in patients with asymptomatic aortic stenosis. Cumulative
event rates were compared with the study population that was divided
according to left ventricular global longitudinal strain (LV GLS) at baseline more
than −18.2% (orange line indicates more impaired) vs −18.2% or less (blue line
indicates more preserved).
Research Original Investigation Association of Left Ventricular Global Longitudinal StrainWith Asymptomatic Severe Aortic Stenosis
E6 JAMA Cardiology Published online August 15, 2018 (Reprinted) jamacardiology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by Patrizio Lancellotti on 08/18/2018
propriate LV hypertrophy,34 and increased valvuloarterial
impedance35). Data demonstrating theprognostic effect of LV
GLS in severe AS and its incremental value over these deter-
minants are accumulating. In a cohort of 395patientswithAS,
including 302 patients with severe AS, Kusunose et al10 dem-
onstrated that LV GLS was an independent predictor of all-
causemortality and had incremental prognostic value on top
of known echocardiographic predictors and symptom status.
However, only 21% of these patients with severe AS were
asymptomatic, and mortality rates were high (25%). Lancel-
lotti et al25 showed in 163 exclusively asymptomatic patients
with severeAS thatLVGLSwas independently associatedwith
the occurrence of cardiac events (ie, symptom development,
eventualAVR, anddeath).Other studieshave investigated the
prognostic effect of LVGLS in asymptomatic AS, but these of-
ten had small patient samples, included moderate AS, or did
not report symptomdevelopmentasanendpoint.6,26-29 Incon-
trast, this study included a larger study population of 220 pa-
tients with asymptomatic severe AS with lowmortality rates
at follow-up (28 patients [13%]) and amore preserved LVGLS
at baseline, thus representing a lower-risk study population
in an earlier disease stage of severe AS. In addition, this study
demonstrated that the natural course of LV GLS is character-
ized by further deterioration over time. These results provide
further insights into the currently available literature by con-
firming that LV GLS is a sensitivemarker for subclinical myo-
cardial dysfunction andmight aid in identifying patientswho
are at risk for symptom development and the need for inter-
vention. Therefore, the present evaluation corroborates that
LV GLS holds promise in the preoperative assessment of pa-
tientswith asymptomatic severe ASwithout overt signs of LV
dysfunction, although further prospective research is needed
to determine the exact role of LV GLS in predicting AS pro-
gression and severity.
Clinical Implications
In patients with symptomatic severe AS, it has been demon-
strated thatmyocardial fibrosis can be present and persist af-
ter AVR.21 Diffusemyocardial fibrosis that was noninvasively
assessed by native T1 mapping on cardiac magnetic reso-
nance imagingwaspresent in asymptomatic patientswith se-
vere AS and was associated with LV GLS that was measured
byspeckle trackingechocardiography.36This studyshows that
LV GLS is often impaired in asymptomatic severe AS and will
further deteriorate if left untreated, while LVEF remains un-
changed. This suggests that patients with impaired LV GLS at
baselinehave subclinicalmyocardial dysfunction that is prob-
ably secondary todiffuse fibrosis,which isnotdetectedby the
conventionalechocardiographicparametersofLVsystolic func-
tion. Therefore, the evaluationof LVGLSand considerationof
objective signs of AS-related cardiac damage in patients with
asymptomatic severeASwithpreservedLVEF (as recently sug-
gested in a new AS staging classification37) may help to de-
fine the optimal timing for AVR (before symptom develop-
ment and irreversible myocardial damage occur).
Limitations
This study was limited by its retrospective design, which
could have introduced a selection bias. Left ventricular GLS
was measured using different platforms, which can lead to
slight variations in the quantification of LV systolic dysfunc-
tion when considering the current variability in LV GLS mea-
surements across vendors. Although intervendor differences
in LV GLS measurements have been reported to be statisti-
cally significant, this bias was only moderate and the interob-
server and intraobserver reproducibility of LV GLS were com-
parable with or superior to conventional echocardiographic
parameters, such as LVEF.38,39 Furthermore, the precision of
LV GLS has been shown to be high even in observers with low
experience levels.39 The differences in mean LV GLS values
or in the prevalence of LV systolic dysfunction based on an
LV GLS value of more impaired than −19.6% were not
observed across the participating centers. Finally, as the par-
ticipating centers are tertiary referral hospitals for AVR, refer-
ral bias could be present, with subsequent increased rates of
AVR. The decision of referral for AVR was left to the discre-
tion of the treating cardiologist.
Conclusions
InasymptomaticsevereAS,mostpatientshave impairedLVGLS
at the initial diagnosis despite preserved LVEF. Furthermore,
during follow-up and before intervention, a further deteriora-
tion of LVGLSoccurredwithout a change in LVEF,whereasAS
severity progressed and LV hypertrophy increased. Impaired
LV GLS at baseline was associated with a higher risk of symp-
tomdevelopmentandneedforaorticvalve intervention.There-
fore, assessing LVGLS holds promise in the risk assessment of
asymptomatic severe AS, although further prospective stud-
ies in larger patient populations arewarranted to establish the
exact role of LV GLS, integrated with other markers of AS se-
verity andprogression, in identifyingpatientswhomight ben-
efit from earlier aortic valve intervention.
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